LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix^(TM) in VZV-primed mice  

作　　者：Ning Luan Han Cao Yunfei Wang Kangyang Lin Cunbao Liu 

机构地区：[1]Institute of Medical Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Kunming 650118,China

出　　处：《Virologica Sinica》2022年第5期731-739,共9页中国病毒学（英文版）

基　　金：supported by the Major Science and Technology Special Projects of Yunnan Province,China (202002AA100009);the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2021-JKCS-012);the Special Biomedicine Projects of Yunnan Province (202102AA310035);National Natural Science Foundation of China (82104130);Fundamental Research Funds for the Central Universities (3332021072);the Basic Research Projects of Yunnan Province (202101AU070176, 202101AT070286);the Funds for the Training of High-level Health Technical Personnel in Yunnan Province(grant number H-2019063);the Funds for High-level Scientific and Technological Talents Selection Special Project of Yunnan Province(202205AC160015)

摘　　要：Latent varicella-zoster virus(VZV)may be reactivated to cause herpes zoster,which affects one in three people during their lifetime.The currently available subunit vaccine Shingrix^(TM) is superior to the attenuated vaccine Zostavax®in terms of both safety and efficacy,but the supply of its key adjuvant component QS21 is limited.With ionizable lipid nanoparticles(LNPs)that were recently approved by the FDA for COVID-19 mRNA vaccines as carriers,and oligodeoxynucleotides containing CpG motifs(CpG ODNs)approved by the FDA for a subunit hepatitis B vaccine as immunostimulators,we developed a LNP vaccine encapsulating VZV-glycoprotein E(gE)and CpG ODN,and compared its immunogenicity with Shingrix^(TM) in C57BL/6J mice.The results showed that the LNP vaccine induced comparable levels of gE-specific IgG antibodies to Shingrix^(TM) as determined by enzymelinked immunosorbent assay(ELISA).Most importantly,the LNP vaccine induced comparable levels of cellmediated immunity(CMI)that plays decisive roles in the efficacy of zoster vaccines to Shingrix^(TM) in a VZVprimed mouse model that was adopted for preclinical studies of Shingrix^(TM) .Number of IL-2 and IFN-γsecreting splenocytes and proportion of T helper 1(Th1)cytokine-expressing CD4^(+)T cells in LNP-CpG-adjuvanted VZV-gE vaccinated mice were similar to that of Shingrix^(TM) boosted mice.All of the components in this LNP vaccine can be artificially and economically synthesized in large quantities,indicating the potential of LNP-CpGadjuvanted VZV-gE as a more cost-effective zoster vaccine.

关 键 词：Varicella zoster virus(VZV) Subunit vaccine ADJUVANT Lipid nanoparticle(LNP) CpG oligodeoxynucleotide(CpG ODN) AS01B Humoral immunity Cell-mediated immunity(CMI) 

分 类 号：R392-33[医药卫生—免疫学]